EBIT: Income before interest and taxes.
Larimar Therapeutics, Inc. (LRMR) had EBIT of $-32.46M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-29.71M |
|
-- |
|
-- |
|
$32.46M |
|
$-32.46M |
|
$1.33M |
|
$-31.14M |
|
$-31.14M |
|
$-31.14M |
|
$-31.14M |
|
$-31.14M |
|
$-31.14M |
|
|
EBIT |
$-32.46M |
$-32.97M |
|
104.21M |
|
104.21M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$136.15M |
|
$0.60M |
|
$4.35M |
|
$140.50M |
|
$35.65M |
|
-- |
|
$3.39M |
|
$39.04M |
|
$101.47M |
|
$101.47M |
|
$101.47M |
|
104.63M |
|
| Cash Flow Statement Financials | |
$-119.83M |
|
$0.52M |
|
$110.73M |
|
$86.02M |
|
$77.44M |
|
$-8.58M |
|
$6.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-119.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.69% |
|
-30.69% |
|
-22.16% |
|
-30.69% |
|
$0.97 |
|
$-1.15 |
|
$-1.15 |
|